Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus POLYCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus POLYCILLIN.
OMNIPEN-N vs POLYCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Polycillin (ampicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
250-500 mg orally every 6 hours or 500 mg intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal excretion of unchanged drug accounts for 60-80% via glomerular filtration and tubular secretion; 20-40% is hepatically metabolized and eliminated in bile/feces.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic